Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers – GeneBOPP


Trial ID:NCT04330716

View complete trial on

Protocol #:19-652

877-DF-TRIAL (877-338-7425)

Condition(s):Breast Cancer, Metastatic Prostate Cancer, Ovarian Cancer, Pancreatic Cancer

Phase:Not Applicable

Principal Investigator:Rana, Huma

Site Research Nurse(s):Brule, Maurice, N.
Cronis, Charles, Lewis
Fleming, Norah, Michelle
Freeman, Stefani, Danielle
Gentile, Alissa,
Ginter, Lindsey,
Hixon, Nicole, R.
Kosinski, Michelle,
Loeser, Wendy,
Piper, Audrey, L.

Trial Description:
This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

Eligibility Requirements:
- Potentially eligible participants will be identified via medical record screening and/or in accordance with their clinical visit. A HIPAA waiver of authorization will be obtained by the enrolling Institution as needed to have access to the subject's medical record information for screening of eligibility.
- A member of the study team will approach the potentially eligible participant in clinic and discuss the trial. Potentially eligible participants may choose to discuss participation further with their physician at their appointment
- Age ≥ 18 years
- Breast, ovarian, pancreatic, or metastatic prostate cancer
- No prior cancer genetic testing
- Ability to understand and the willingness to sign an informed consent document
Exclusion Criteria:
- Pregnant
- Prisoners
- Inability to understand English as a spoken language in a healthcare context
- Known hematologic malignancy (e.g. CLL)

Protocol #: 19-652

Questions & Enrollment